Approval Marks Biomerica’s Strategic Entry into Southeast Asia’s Rapidly Growing Healthcare Market Simple, FDA-Cleared At-Home Test Detects an Early Warning Sign of Colorectal Cancer in Minutes ...
Operating Expenses Decline 4% Year-to-Date Balance Sheet Strengthens and Working Capital Improves by 14.7% IRVINE, Calif., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA),...
CMS is the single largest payer for healthcare in the United States, with Medicare responsible for approximately 21% of total healthcare expenditure. The $300 rate will apply to claims approved and paid...
Authorization Covers Multiple Screening Tests for Cancer and Chronic Disease Risk Detection • Portfolio includes tests for colorectal disease, breast self exam, prostate disease, kidney disease,...
Publication details large multicenter clinical trial demonstrating significant reductions in IBS symptoms through inFoods IBS guided dietary therapy IRVINE, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE)...
Rising Demand from Third-Party Diagnostic and Biotechnology Companies Drives CDMO Service Expansion Comprehensive CDMO services now featured on Biomerica’s updated website IRVINE, Calif., Nov....
- Expands Marketing of Non-Drug IBS Symptom Management Test Through One of the Nation’s Most Trusted Health Care Distributors - Relationship Marks a Key Milestone in Biomerica’s Commercialization...
Reported Improved Gross Margin from Contribution from Higher-Margin Product Mix Operating Expenses Continued to Decline Compared to the First Quarter of the Prior Fiscal Year, Reflecting the Company’s...
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Biomerica...
Brings decades of leadership in laboratory testing, clinical diagnostics, payor strategy, and sales growth Extensive track record in commercializing advanced laboratory testing and insurer strategies...